JP2016510594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510594A5 JP2016510594A5 JP2015561628A JP2015561628A JP2016510594A5 JP 2016510594 A5 JP2016510594 A5 JP 2016510594A5 JP 2015561628 A JP2015561628 A JP 2015561628A JP 2015561628 A JP2015561628 A JP 2015561628A JP 2016510594 A5 JP2016510594 A5 JP 2016510594A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- heparanase
- cells
- specific
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772591P | 2013-03-05 | 2013-03-05 | |
| US61/772,591 | 2013-03-05 | ||
| PCT/US2014/020936 WO2014138315A1 (en) | 2013-03-05 | 2014-03-05 | Heparanase expression in human t lymphocytes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510594A JP2016510594A (ja) | 2016-04-11 |
| JP2016510594A5 true JP2016510594A5 (https=) | 2017-04-06 |
Family
ID=50397277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561628A Ceased JP2016510594A (ja) | 2013-03-05 | 2014-03-05 | Ｔリンパ球におけるヘパラナーゼの発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160017302A1 (https=) |
| EP (1) | EP2964253A1 (https=) |
| JP (1) | JP2016510594A (https=) |
| CN (1) | CN105407914A (https=) |
| AU (1) | AU2014225708B2 (https=) |
| CA (1) | CA2904236A1 (https=) |
| HK (1) | HK1220111A1 (https=) |
| WO (1) | WO2014138315A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| JP6681837B2 (ja) | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| CA3280968A1 (en) * | 2015-04-23 | 2025-10-30 | Baylor College Of Medicine | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same |
| WO2016187459A1 (en) | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| WO2016196388A1 (en) * | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| SG11201803419PA (en) * | 2015-10-30 | 2018-05-30 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
| WO2017117521A1 (en) * | 2015-12-31 | 2017-07-06 | Berkeley Lights, Inc. | Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide |
| EP3548055A4 (en) | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| CN110546495B (zh) | 2016-12-30 | 2022-11-01 | 加利福尼亚州立大学董事会 | 用于基因组编辑t细胞的选择和传代的方法 |
| WO2018175476A1 (en) * | 2017-03-20 | 2018-09-27 | Baylor College Of Medicine | Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20210104772A (ko) | 2018-12-14 | 2021-08-25 | 블루버드 바이오, 인코포레이티드. | 이량체화제로 조절된 면역수용체 복합체 |
| BR112021020999A2 (pt) | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| KR20220031549A (ko) | 2019-05-08 | 2022-03-11 | 2세븐티 바이오, 인코포레이티드 | Cll-1 표적화 면역요법 |
| CN114450397A (zh) * | 2019-08-01 | 2022-05-06 | 纪念斯隆-凯特琳癌症中心 | 用于改善免疫疗法的细胞及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5968822A (en) * | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CA2432157A1 (en) * | 2000-12-19 | 2002-06-27 | Insight Strategy And Marketing Ltd. | The use of ecm degrading enzymes for the improvement of cell transplantation |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US8093031B2 (en) * | 2005-09-20 | 2012-01-10 | Carmel-Haifa University Economic Corp. Ltd. | Heparanases and splice variants thereof, polynucleotides encoding them and uses thereof |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2012033885A1 (en) * | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
-
2014
- 2014-03-05 CA CA2904236A patent/CA2904236A1/en not_active Abandoned
- 2014-03-05 WO PCT/US2014/020936 patent/WO2014138315A1/en not_active Ceased
- 2014-03-05 US US14/773,330 patent/US20160017302A1/en not_active Abandoned
- 2014-03-05 JP JP2015561628A patent/JP2016510594A/ja not_active Ceased
- 2014-03-05 EP EP14714474.5A patent/EP2964253A1/en not_active Withdrawn
- 2014-03-05 CN CN201480025440.0A patent/CN105407914A/zh active Pending
- 2014-03-05 AU AU2014225708A patent/AU2014225708B2/en not_active Expired - Fee Related
- 2014-03-05 HK HK16108046.9A patent/HK1220111A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510594A5 (https=) | ||
| MX2023001878A (es) | Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t. | |
| EP4643874A3 (en) | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy | |
| PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
| MX2023012264A (es) | Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico. | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
| WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
| MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| MY205684A (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| EP4219689A3 (en) | Immune effector cell therapies with enhanced efficacy | |
| CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| WO2013040557A3 (en) | Rna engineered t cells for the treatment of cancer | |
| EP4279086A3 (en) | Compositions and methods for treating cancer with anti-cd19 immunotherapy | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| MX2017004691A (es) | Bloqueo de cd73. | |
| MX372883B (es) | Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. |